Orygen: Clinical Trials

2 trials sponsored by Orygen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 unknown. 2 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32Completed 1, Unknown 1
Phase 21Unknown 1

Follow Orygen: new trials by email

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Staged Treatment in Early Psychosis Study
Support and Problem Solving Therapy, Cognitive Behavioural Case Management, Fluoxetine - Psychotic Disorders, Personality Disorders
Phase 3CompletedOrygen3422016-04-012025-10-02
Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
omega-3 PUFAs, Standard care, placebo - 22q11 Deletion Syndrome
Phase 2 / Phase 3UnknownBambino Gesù Hospital and Research Institute802014-06-012014-02-25

Conditions studied

Psychotic Disorders (2)  ·  22q11 Deletion Syndrome (1)  ·  Personality Disorders (1)

Interventions

Fish Oils (1)  ·  Fluoxetine (1)  ·  Palliative Care (1)  ·  Standard of Care (1)

Countries

Australia (1)  ·  Holy See (1)

Top investigators

Marco Armando, MD, PhD (1)  ·  Patrick McGorry, MD, PhD (1)

Results publications

PMID 37378974

NIH funding

U01MH105258 (1)